FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4220794893> ?p ?o ?g. }

• W4220794893 endingPage "866" @default.
• W4220794893 startingPage "858" @default.
• W4220794893 abstract "In preclinical models of prostate cancer (PC), disulfiram (DSF) reduced tumor growth only when co-administered with copper (Cu), and Cu uptake in tumors is partially regulated by androgen-receptor signaling. However, prior trials of DSF in PC used DSF as monotherapy.To assess the safety and efficacy of concurrent administration of DSF with Cu, we conducted a phase 1b clinical trial of patients with metastatic castration-resistant prostate cancer (mCRPC) receiving Cu with DSF.Patients with mCRPC were treated in two cohorts: mCRPC with nonliver/peritoneal metastases (A), and mCRPC with liver and/or peritoneal metastases (B). Baseline Cu avidity was measured by 64 CuCl2 PET scan. Intravenous (IV) CuCl2 was given weekly for three doses with oral daily DSF followed by daily oral Cu gluconate and DSF until disease progression. DSF and metabolite diethyldithiocarbamic acid methyl ester (Me-DDC) levels in plasma were measured. DSF and Me-DDC were then assessed for cytotoxicity in vitro.We treated nine patients with mCRPC (six on cohort A and three on cohort B). Bone and nodal metastases showed differential and heterogeneous Cu uptake on 64 CuCl2 PET scans. No confirmed PSA declines or radiographic responses were observed. Median PFS was 2.8 months and median OS was 8.3 months. Common adverse events included fatigue and psychomotor depression; no Grade 4/5 AEs were observed. Me-DDC was measurable in all samples (LOQ = 0.512 ng/ml), whereas DSF was not (LOQ = 0.032 ng/ml, LOD = 0.01 ng/ml); Me-DDC was not cytotoxic in vitro.Oral DSF is not an effective treatment for mCRPC due to rapid metabolism into an inactive metabolite, Me-DDC. This trial has stopped enrollment and further work is needed to identify a stable DSF formulation for treatment of mCRPC." @default.
• W4220794893 created "2022-04-03" @default.
• W4220794893 creator A5000997350 @default.
• W4220794893 creator A5033077569 @default.
• W4220794893 creator A5033138240 @default.
• W4220794893 creator A5033835226 @default.
• W4220794893 creator A5037077868 @default.
• W4220794893 creator A5038489185 @default.
• W4220794893 creator A5045891896 @default.
• W4220794893 creator A5047007251 @default.
• W4220794893 creator A5047408345 @default.
• W4220794893 creator A5053535513 @default.
• W4220794893 creator A5077635587 @default.
• W4220794893 creator A5079793514 @default.
• W4220794893 creator A5087517818 @default.
• W4220794893 creator A5089713876 @default.
• W4220794893 creator A5090604007 @default.
• W4220794893 creator A5091070593 @default.
• W4220794893 date "2022-03-14" @default.
• W4220794893 modified "2023-10-16" @default.
• W4220794893 title "Prospective clinical trial of disulfiram plus copper in men with metastatic castration‐resistant prostate cancer" @default.
• W4220794893 cites W1972579292 @default.
• W4220794893 cites W2045316168 @default.
• W4220794893 cites W2065550384 @default.
• W4220794893 cites W2084541153 @default.
• W4220794893 cites W2084605477 @default.
• W4220794893 cites W2134077541 @default.
• W4220794893 cites W2147536399 @default.
• W4220794893 cites W2148629267 @default.
• W4220794893 cites W2150865892 @default.
• W4220794893 cites W2214621962 @default.
• W4220794893 cites W2278392405 @default.
• W4220794893 cites W2618014440 @default.
• W4220794893 cites W2737601741 @default.
• W4220794893 cites W2752207078 @default.
• W4220794893 cites W2882972309 @default.
• W4220794893 cites W2900909713 @default.
• W4220794893 cites W2903064535 @default.
• W4220794893 cites W2912845066 @default.
• W4220794893 cites W2946916423 @default.
• W4220794893 cites W2947014957 @default.
• W4220794893 cites W2947893479 @default.
• W4220794893 cites W2963794755 @default.
• W4220794893 cites W3119005666 @default.
• W4220794893 cites W3013510958 @default.
• W4220794893 doi "https://doi.org/10.1002/pros.24329" @default.
• W4220794893 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35286730" @default.
• W4220794893 hasPublicationYear "2022" @default.
• W4220794893 type Work @default.
• W4220794893 citedByCount "7" @default.
• W4220794893 countsByYear W42207948932023 @default.
• W4220794893 crossrefType "journal-article" @default.
• W4220794893 hasAuthorship W4220794893A5000997350 @default.
• W4220794893 hasAuthorship W4220794893A5033077569 @default.
• W4220794893 hasAuthorship W4220794893A5033138240 @default.
• W4220794893 hasAuthorship W4220794893A5033835226 @default.
• W4220794893 hasAuthorship W4220794893A5037077868 @default.
• W4220794893 hasAuthorship W4220794893A5038489185 @default.
• W4220794893 hasAuthorship W4220794893A5045891896 @default.
• W4220794893 hasAuthorship W4220794893A5047007251 @default.
• W4220794893 hasAuthorship W4220794893A5047408345 @default.
• W4220794893 hasAuthorship W4220794893A5053535513 @default.
• W4220794893 hasAuthorship W4220794893A5077635587 @default.
• W4220794893 hasAuthorship W4220794893A5079793514 @default.
• W4220794893 hasAuthorship W4220794893A5087517818 @default.
• W4220794893 hasAuthorship W4220794893A5089713876 @default.
• W4220794893 hasAuthorship W4220794893A5090604007 @default.
• W4220794893 hasAuthorship W4220794893A5091070593 @default.
• W4220794893 hasConcept C121608353 @default.
• W4220794893 hasConcept C126322002 @default.
• W4220794893 hasConcept C126894567 @default.
• W4220794893 hasConcept C143998085 @default.
• W4220794893 hasConcept C197934379 @default.
• W4220794893 hasConcept C2775832370 @default.
• W4220794893 hasConcept C2777899217 @default.
• W4220794893 hasConcept C2778523461 @default.
• W4220794893 hasConcept C2780192828 @default.
• W4220794893 hasConcept C71924100 @default.
• W4220794893 hasConcept C72563966 @default.
• W4220794893 hasConcept C90924648 @default.
• W4220794893 hasConcept C98274493 @default.
• W4220794893 hasConceptScore W4220794893C121608353 @default.
• W4220794893 hasConceptScore W4220794893C126322002 @default.
• W4220794893 hasConceptScore W4220794893C126894567 @default.
• W4220794893 hasConceptScore W4220794893C143998085 @default.
• W4220794893 hasConceptScore W4220794893C197934379 @default.
• W4220794893 hasConceptScore W4220794893C2775832370 @default.
• W4220794893 hasConceptScore W4220794893C2777899217 @default.
• W4220794893 hasConceptScore W4220794893C2778523461 @default.
• W4220794893 hasConceptScore W4220794893C2780192828 @default.
• W4220794893 hasConceptScore W4220794893C71924100 @default.
• W4220794893 hasConceptScore W4220794893C72563966 @default.
• W4220794893 hasConceptScore W4220794893C90924648 @default.
• W4220794893 hasConceptScore W4220794893C98274493 @default.
• W4220794893 hasFunder F4320306536 @default.
• W4220794893 hasFunder F4320309523 @default.
• W4220794893 hasIssue "7" @default.
• W4220794893 hasLocation W42207948931 @default.

• next